- Home
- EBS vs KALV Comparison
EBS vs KALV Comparison
Compare EBS & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EBS
- KALV
- Stock Information
- Founded
- EBS 1998
- KALV N/A
- Country
- EBS United States
- KALV United States
- Employees
- EBS N/A
- KALV N/A
- Industry
- EBS Biotechnology: Pharmaceutical Preparations
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- EBS Health Care
- KALV Health Care
- Exchange
- EBS Nasdaq
- KALV Nasdaq
- Market Cap
- EBS 353.9M
- KALV 642.3M
- IPO Year
- EBS 2006
- KALV N/A
- Fundamental
- Price
- EBS $7.30
- KALV $14.31
- Analyst Decision
- EBS Strong Buy
- KALV Strong Buy
- Analyst Count
- EBS 3
- KALV 9
- Target Price
- EBS $14.33
- KALV $26.29
- AVG Volume (30 Days)
- EBS 1.4M
- KALV 2.0M
- Earning Date
- EBS 08-05-2025
- KALV 07-10-2025
- Dividend Yield
- EBS N/A
- KALV N/A
- EPS Growth
- EBS N/A
- KALV N/A
- EPS
- EBS N/A
- KALV N/A
- Revenue
- EBS $965,400,000.00
- KALV N/A
- Revenue This Year
- EBS N/A
- KALV N/A
- Revenue Next Year
- EBS $18.88
- KALV $347.19
- P/E Ratio
- EBS N/A
- KALV N/A
- Revenue Growth
- EBS N/A
- KALV N/A
- 52 Week Low
- EBS $4.02
- KALV $7.30
- 52 Week High
- EBS $15.10
- KALV $16.32
- Technical
- Relative Strength Index (RSI)
- EBS 62.33
- KALV 58.58
- Support Level
- EBS $6.59
- KALV $11.10
- Resistance Level
- EBS $7.29
- KALV $16.32
- Average True Range (ATR)
- EBS 0.39
- KALV 1.10
- MACD
- EBS 0.05
- KALV 0.36
- Stochastic Oscillator
- EBS 92.89
- KALV 68.95
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.